Chronic Obstructive Pulmonary Disease (COPD)

Sep 12, 2025

COPD management has progressively centered on bronchodilator-based regimens, with Long-acting Muscarinic Antagonists (LAMAs) and Long-acting Beta-agonists (LABAs) forming the therapeutic core. Dual LAMA/LABA therapy is standard for moderate disease, while triple therapy with Inhaled Corticosteroids (ICS) is reserve...

Dec 20, 2024

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, according to the World Health Organization (WHO). It affects approximately 251 million people worldwide. Smoking is the leading cause of COPD, responsible for around 70-90% of cases. However, exposure to air pollution, occupa...

May 31, 2023

DUPIXENT has shown positive pivotal results for COPD, confirming the key role of IL-4 and IL-13 in type 2 inflammatory diseases. DUPIXENT has the potential to be the first biologic with unprecedented and paradigm-shifting clinical results to treat COPD, having demonstrated a statistically significant reduc...